Free Trial

Humacyte (HUMA) Competitors

Humacyte logo
$2.50 -0.04 (-1.38%)
Closing price 03:59 PM Eastern
Extended Trading
$2.51 +0.00 (+0.20%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUMA vs. CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, BGM, and ABCL

Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), BGM Group (BGM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

Humacyte vs. Its Competitors

CureVac (NASDAQ:CVAC) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 5.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CureVac presently has a consensus price target of $6.83, suggesting a potential upside of 25.27%. Humacyte has a consensus price target of $11.71, suggesting a potential upside of 367.64%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Humacyte
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

CureVac has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$523.70M2.34$175.50M$0.925.93
Humacyte$1.57M247.50-$148.70M-$0.69-3.63

In the previous week, Humacyte had 8 more articles in the media than CureVac. MarketBeat recorded 10 mentions for Humacyte and 2 mentions for CureVac. CureVac's average media sentiment score of 0.89 beat Humacyte's score of 0.48 indicating that CureVac is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CureVac
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Humacyte
1 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CureVac has a net margin of 35.44% compared to Humacyte's net margin of 0.00%. CureVac's return on equity of 30.89% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac35.44% 30.89% 25.54%
Humacyte N/A N/A -73.59%

CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Summary

CureVac beats Humacyte on 9 of the 17 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HUMA vs. The Competition

MetricHumacyteMED IndustryMedical SectorNASDAQ Exchange
Market Cap$388.58M$2.96B$5.57B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-3.6321.1627.2120.15
Price / Sales247.50260.59416.26185.35
Price / CashN/A41.8337.0657.97
Price / Book-6.117.768.085.60
Net Income-$148.70M-$54.96M$3.16B$248.50M
7 Day Performance10.60%5.99%3.74%5.11%
1 Month Performance-6.18%4.41%3.88%7.58%
1 Year Performance-56.21%6.36%34.26%21.53%

Humacyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HUMA
Humacyte
2.761 of 5 stars
$2.51
-1.4%
$11.71
+367.6%
-56.6%$388.58M$1.57M-3.63150News Coverage
Analyst Forecast
CVAC
CureVac
4.7393 of 5 stars
$5.43
+0.9%
$6.83
+25.8%
+79.7%$1.22B$579.18M5.90880
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
GPCR
Structure Therapeutics
2.6963 of 5 stars
$20.74
-1.6%
$76.17
+267.2%
-51.5%$1.19BN/A-23.84136
AUPH
Aurinia Pharmaceuticals
2.7526 of 5 stars
$8.47
-2.0%
$11.50
+35.8%
+52.0%$1.14B$235.13M30.25300
NAGE
Niagen Bioscience
1.3354 of 5 stars
$14.41
+1.3%
$19.50
+35.3%
N/A$1.14B$107.93M84.76120
AMPH
Amphastar Pharmaceuticals
4.4249 of 5 stars
$22.96
-0.5%
$32.33
+40.8%
-39.3%$1.08B$730.66M8.322,028
DYN
Dyne Therapeutics
3.4888 of 5 stars
$9.52
-0.5%
$41.13
+332.0%
-76.1%$1.08BN/A-2.65100
PAHC
Phibro Animal Health
3.7012 of 5 stars
$25.54
-0.5%
$21.80
-14.6%
+83.1%$1.04B$1.02B32.741,940Analyst Upgrade
BGM
BGM Group
N/A$10.59
-11.5%
N/AN/A$1.03B$25.10M0.00298
ABCL
AbCellera Biologics
2.5608 of 5 stars
$3.43
-5.0%
$8.33
+143.0%
+49.6%$1.02B$28.83M-6.12500News Coverage
Analyst Forecast
Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:HUMA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners